Significant A1C reductions1
An open-label, parallel-group, noninferiority trial of 582 insulin-naïve men and women with type 2 diabetes. Patients were randomized 1:1 to receive Lantus® (n=291) or detemir (n=291) once daily (in the evening) as add-on therapy to oral glucose-lowering drugs. Both insulins were titrated to FPG target of ≤108 mg/dL. An additional morning dose of detemir was allowed if predinner plasma glucose was >126 mg/dL after achievement of fasting plasma glucose of <126 mg/dL or nocturnal hypoglycemia precluded achievement of FPG target. Participants were eligible if A1C ranged from 7.5% to 10%. Primary endpoint was change in A1C at end of treatment period.
See how Lantus® provides effective, improved glycemic control in diabetes patients.†
†Lantus® Prescribing Information. August 2015.
Lantus® is a once-daily, long-acting insulin.**
**Lantus® Prescribing Information. August 2015.
Lantus® is a basal insulin with demonstrated long-term CV safety data††